Friulchem Logo

Friulchem

CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.

FCM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005378457 (+1 more)
LEI:
8156003DC8C04217A094
Country:
Italy
Address:
VIA SAN MARCO, 23, 33099 VIVARO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Friulchem is a Contract Development and Manufacturing Organization (CDMO) exclusively dedicated to the animal health sector. The company researches, develops, and manufactures veterinary pharmaceuticals, food supplements, complementary feeds, and premixes for both livestock and pets. Its GMP-authorized services include micronization, granulation, mixing, and spray drying, supported by proprietary drug delivery technologies. Friulchem offers customized formulations and has developed innovative products such as Fc-Cubes®, a highly palatable chewable tablet for pets. Operating on a B2B model, the company provides integrated solutions from development to full-scale manufacturing and packaging at its facilities in Italy and France.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-13 18:49
Delisting Announcement
Modulo Dich. Recesso Friulchem SpA
Italian 610.4 KB
2024-12-23 12:22
Delisting Announcement
REVOCA DELL'AMMISSIONE ALLA NEGOZIAZIONE SU EGM DELLE AZIONI EMESSE DALLA SOCIE…
Italian 205.2 KB
2024-12-07 09:58
Pre-Annual General Meeting Information
Friulchem - Avviso Convocazione - v. 08 - DWF - 2024.12.06 - Final
Italian 335.9 KB
2024-12-07 09:57
Delisting Announcement
CS _Convocazione assemblea Revoca_v. 10 - DWF - 2024.12.06 - Final
Italian 185.5 KB
2024-09-29 16:58
Earnings Release
CS APPROVAZIONE RELAZIONE SEMESTRALE CONSOLIDATA FRIULCHEM SPA
Italian 680.5 KB
2024-04-22 17:44
AGM Information
Approvazione assemblea Friulchem - Convocazione assemblea 8 maggio
Italian 283.4 KB
2024-04-05 11:31
Pre-Annual General Meeting Information
AVVISO DI MESSA A DISPOSIZIONE DOCUMENTAZIONE RELATIVA ALL’ASSEMBLEA DEGLI AZIO…
Italian 211.1 KB
2024-04-05 11:30
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA E STRAORDINARIA 2023
Italian 349.9 KB
2024-04-04 15:02
Pre-Annual General Meeting Information
verifica dei requisiti di indipendenza e convocazione assemblea straordinaria
Italian 113.0 KB
2024-03-22 18:03
Earnings Release
CdA di Friulchem approva il bilancio consolidato e il progetto di bilancio al 3…
Italian 358.5 KB
2024-01-15 15:00
Report Publication Announcement
CALENDARIO EVENTI SOCIETARI 2024
Italian 138.6 KB
2023-09-22 17:36
Earnings Release
IL CONSIGLIO DI AMMINISTRAZIONE DI FRIULCHEM HA APPROVATO LA RELAZIONE CONSOLI…
Italian 965.1 KB
2023-06-08 10:10
Related Party Transaction
FRIULCHEM APPROVA LA DELIBERA QUADRO INERENTE AL CONTRATTO DI FORNITURA DI MATE…
Italian 149.2 KB
2023-04-21 17:16
AGM Information
L’ASSEMBLEA ORDINARIA DEGLI AZIONISTI DI FRIULCHEM
Italian 440.8 KB
2023-04-06 08:28
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA DEGLI AZIONISTI FRIULCHEM S.P.A.
Italian 215.5 KB

Automate Your Workflow. Get a real-time feed of all Friulchem filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Friulchem

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Friulchem via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America
MLYS
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America
INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America
MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America
MIRM
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium
MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan
4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea
142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden
MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534

Talk to a Data Expert

Have a question? We'll get back to you promptly.